J&J shares hit new high on strong drug sales, weaker dollar
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Piper Jaffray Raises Price Target on Johnson & Johnson (JNJ) Following 1Q Report
April 20, 2016 7:42 AM EDTPiper Jaffray reiterated a Neutral rating on Johnson & Johnson (NYSE: JNJ), and raised the price target to $106.00 (from $105.00), following the company's 1Q earnings report. In Pharma, total sales of $8.2B and key drug sales were slightly better than estimates. The Medical Device segment generated revenue of $6.11B,... More
